Treatment Registry
TR-1033 ActiveRecorded October 2026

Compounded semaglutide

Sold by Gide Health · Injection · device not recorded · every compounded semaglutide record

The program identifies an injection, but the delivery device has not been established.

Price

No comparable monthly price verified at this reading. See dated notes for any advertised starting figures.

Visit Gide Health

We earn nothing from this link. It opens Gide Health's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

Sourcing and terms

PharmacyNot disclosed
StatesNot disclosed
PrescriberAsynchronous review
CancellationThe terms say all purchases are final and no refunds are available once services have commenced or the prescription has been sent to the pharmacy. The reviewed public terms do not establish a recurring-plan cancellation deadline. https://www.gide.health/terms-of-service The weight-loss page separately advertises a weight-loss money-back guarantee; its relationship to the final-sales terms is unresolved. https://www.gide.health/weight-loss
MembershipNot disclosed
Consult feeIncluded in program price; itemized amount is not published. Gide's FAQ says the doctor's visit, prescription medication and shipping are included in its plans. It does not establish a separately payable consultation charge. https://www.gide.health/faq

Recorded from gide.health. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. October 2026 — Gide's homepage names compounded semaglutide and tirzepatide injection programs. Its clinical FAQ identifies Beluga Health and describes a medical-history review; a mandatory live video visit is not established. https://www.gide.health/ https://www.gide.health/faq
  2. 2. October 2026 — The product page advertises a starting $209/month, and the category separately advertises offers with different stated plan terms. The selected dose, payment schedule and renewal charge are not established. No payable price is established here. https://www.gide.health/product-details/glp-1-injection https://www.gide.health/weight-loss
  3. 3. October 2026 — The FAQ excludes GLP-1 patients in Arkansas, Louisiana, Mississippi and New Mexico; the terms list only Louisiana, Mississippi and New Mexico. An affirmative program coverage roster is not established. The FAQ also names Jungle Jim's Pharmacy, says it cannot dispense sterile compounds, and gives inconsistent pharmacy licensure counts. That is not confirmation of this program's dispensing pharmacy. https://www.gide.health/faq https://www.gide.health/terms-of-service
  4. 4. October 2026 — The weight-loss page advertises 'Lose 15% of your body weight or your money back', while the terms say purchases are final after services commence or a prescription goes to the pharmacy. The public sources do not reconcile that guarantee with the refund restrictions or establish its full eligibility and exclusions. https://www.gide.health/weight-loss https://www.gide.health/terms-of-service

5 further notes concern other Gide Health programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-1033
Medication category
compounded semaglutide
Readings
1

Related records

Cite this entry

Treatment Registry. (2026). Gide Health — compounded semaglutide (TR-1033). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-1033

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.